Tirzepatide Users Gain Strength With Resistance Training, Study Finds

Adults taking tirzepatide lost less lean tissue and built muscle strength when they combined the medication with resistance training during a 40-week trial.

Both Groups Lost Similar Total Weight Despite Exercise

The 40-week trial assigned 120 adults to either three resistance-training sessions a week or their usual activities while all participants received tirzepatide injections, as reported in Nature Medicine on November 9, 2026. The study included male subjects and postmenopausal women aged 50 to 70 who had overweight or obesity accompanied by a related health condition.

Both groups lost about 22 kilograms of total body weight. Those in the exercise group lost an average of 3.57 kilograms of lean soft tissue. They compared with 4.67 kilograms among those receiving the medication alone, showing a difference of 1.1 kilograms.

Participants receiving tirzepatide alone lost 17.2 kilograms of fat. This compared with 18 kilograms among those undertaking resistance training. Both groups experienced comparable reductions in waist circumference and body mass index.

The 120 participants were split into two arms. A total of 61 subjects stuck to their standard routines while taking tirzepatide once a week. Another 59 individuals engaged in progressive muscle-building workouts like squats and deadlifts three times weekly supervised by an expert exercise physiologist.

Medication therapy began at a 2.5 mg dosage and escalated every 4 weeks. It ultimately achieved a peak dose of 15 mg in two-thirds of the subjects. Eli Lilly supplied the medication, and several authors disclosed payments or advisory relationships with pharmaceutical or nutrition companies.

Content cover image
Photo: Nature

Resistance Training Increased Strength While Drug-Only Group Weakened

Bench press and knee extension performance were among the measures showing that upper and lower body strength rose in the exercising cohort. They dropped in the group receiving only the drug. The gym-goers became stronger in tests of both upper and lower body strength. People taking the drugs alone got weaker, according to The Independent.

Trial participants who performed resistance exercises increased their muscle strength across several movements. Gains included 10.7% on the bench press, 15.7% on the lat pull-down, and 17.5% on knee stretching.

The drug-only group experienced a decrease in upper and lower body muscle performance. They had reductions of 8.4% on the bench press, 6.5% on the lat pull-down, and 9% on knee stretching. Compared to the group receiving the medication alone, the muscle strength gap by body part widened by 18.8 to 23.4%.

Endocrinologist Professor Bu Yeap said that the trial was a world first in investigating whether exercise could stop muscle loss during rapid weight loss. Participants David Burchett and Stephen Johnson combined weight loss injections with heavy lifting during the research. “I felt so much stronger at the end of the trial than I did at the very beginning,” Burchett said.

Tirzepatide Users Gain Strength With Resistance Training, Study Finds
Photo: Washington Post

Johnson lost more than 25 kilograms and continued going to the gym afterward. He said, “If you don’t do the physical training, you’re selling yourself short.” Professor Yeap said that people should be encouraged to perform resistance exercise to prevent frailty.

“Strength is a more important outcome than muscle mass, because it relates to function and frailty,” said Daniel Green, an exercise physiologist at the University of Western Australia.

Green said that therapies should focus on preserving physical performance as pounds drop. He advised physicians to integrate resistance workouts into patient care plans. “We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment,” Green said in a university statement.

Both Groups Saw Comparable Cardiometabolic Improvements

Both treatment groups achieved similar cardiometabolic improvements. They had a fall in systolic blood pressure of 15 to 17 mmHg, along with reductions in diastolic blood pressure and improvements in blood glucose, insulin, and glycated hemoglobin, as detailed by News-Medical.

Eli Lilly supplied the medication for the study and had no role in designing, running, or evaluating the investigator-initiated trial, according to The Jerusalem Post.